Aldosterone synthase inhibition for treatment of people with chronic kidney disease
Clicks: 16
ID: 320527
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
4.5
/100
16 views
6 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #25 of 150 articles by views in clinical kidney journal
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 150 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Aldosterone contributes to the progression of chronic kidney disease (CKD) not only through its effects on blood pressure (BP) but also by promoting inflammation and fibrosis in the kidney and cardiovascular system. Despite contemporary treatment with renin–angiotensin system inhibitors, mineralocorticoid receptor antagonists, and sodium–glucose cotransporter 2 (SGLT2) inhibitors, residual risk persists for adverse kidney and cardiovascular outcomes. Aldosterone synthase inhibition (ASI) has emerged as a potent strategy to directly suppress aldosterone production. Several selective inhibitors, including baxdrostat, lorundrostat, and vicadrostat, have been shown to lower aldosterone levels without affecting cortisol synthesis in a clinically meaningful manner. Clinical studies in hypertension consistently show a decrease in systolic BP with these agents. In a CKD population, vicadrostat dose-dependently reduced the urinary albumin-to-creatinine ratio with additional BP lowering, and possibly greater albuminuria reduction when combined with empagliflozin. Similar findings have been observed with lorundrostat and baxdrostat in patients with CKD and uncontrolled hypertension. Median increases in serum potassium of approximately 0.3 mmol/L that have been observed with ASI were generally manageable in clinical trial populations. Emerging evidence from clinical trials and meta-analyses suggests that concomitant SGLT2 inhibitor therapy may mitigate the risk of clinically significant hyperkalemia, also supporting the use of combination therapy. Overall, ASI provide a potentially beneficial approach to reduce residual risks of CKD. Several phase 3 trials testing vicadrostat or baxdrostat across different populations with CKD, hypertension, or cardiovascular disease will determine whether favourable effects on albuminuria translate into improved kidney and cardiovascular outcomes.
| Reference Key |
openalex_W7167891478
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Katherine R. Tuttle, Jasna B Trbojevic-Stankovic, Radica Z. Alicic, Maria Luiza Caramori, David Cherney, Ricardo Correa Rotter, William G. Herrington, Parminder K Judge, Adeera Levin, P Rossing |
| Journal | clinical kidney journal |
| Year | 2026 |
| DOI |
10.1093/ckj/sfag229
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.